The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback